The management of prostate cancer patients is rapidly changing. The extended survival seen in randomized phase III trials with new molecules has significantly enriched the therapeutic armamentarium, and ongoing clinical trials are assessing whether the integration of these active drugs within established therapeutic regimens results in a further benefit for patients. This complex scenario is raising the need for the identification and validation of biomarkers able to drive the decision-making process during the course of the disease. Compelling evidence has documented the role of microRNAs in cancer biology, and their multifaceted biological activity makes them an attractive candidate as diagnostic, prognostic, and predictive biomarkers. This review summarizes the current knowledge about microRNA deregulation in prostate cancer, how these molecules have been investigated in the clinical setting, and strategies investigators should consider for sharpening their potential.
Written by:
Maugeri-Saccà M, Coppola V, Bonci D, De Maria R Are you the author?
From the "Regina Elena" National Cancer Institute and †Department of Hematology,Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Reference: Cancer J. 2012 May;18(3):253-61
doi: 10.1097/PPO.0b013e318258b5b6
PubMed Abstract
PMID: 22647362